ARCHIVES

DCE Advisors Okay Study Of Cancer Risk in Breast Augmentation

This article is from The Cancer Letter archive.

Vol. 17 No. 45 | November 22, 1991

Download PDF Visit The Full Archive

Related Articles

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

November 26, 2010

AACR Using Its Clout To Urge Higher NCI Budget

May 24, 1991

OMB Ploy Would Delay Funding 1,500 NIH Grants From FY 1985 To 1986; Other Cuts Are Considered

January 18, 1985

CCRAC Calls for New Comp Center, Community Hospital Core Grants For Control Development

August 24, 1979

DCT Board Ok’s concept For In Vivo Combination Studies

November 23, 1990

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

December 26, 2014